Lecanemab, a newly approved immunotherapy in Malaysia, offers a potential breakthrough in Alzheimer’s disease treatment for patients in the early stages of the illness. Recent data suggests the drug may sluggish cognitive decline by as much as eight years, representing a significant advancement over existing symptomatic treatments. Approval from the National Pharmaceutical Regulatory Agency (NPRA) occurred in January, with Subang Jaya Medical Centre becoming the first facility in the country to administer the medication.
Alzheimer’s disease, a devastating neurodegenerative condition, currently affects millions worldwide and poses an increasing public health challenge, particularly in rapidly aging populations. While previous treatments focused on managing symptoms, lecanemab targets the underlying pathology of the disease, offering a potential to modify its course. This represents a paradigm shift in Alzheimer’s care, moving beyond palliative measures towards disease alteration.
In Plain English: The Clinical Takeaway
- It Doesn’t Cure, But Slows Down: Lecanemab doesn’t reverse Alzheimer’s, but it can significantly delay the worsening of symptoms, potentially giving patients more years of independent living.
- Early Detection is Key: This drug only works in the very early stages of Alzheimer’s, so getting a diagnosis as soon as possible is crucial. Specialized tests are needed to confirm the diagnosis.
- It’s Not Without Risks: Like all medications, lecanemab has potential side effects, including brain swelling and bleeding, which require careful monitoring.
Understanding Lecanemab’s Mechanism of Action
Alzheimer’s disease is characterized by the accumulation of two abnormal proteins in the brain: amyloid and tau. Amyloid plaques, formed from the amyloid-beta protein, are believed to be one of the earliest pathological hallmarks of the disease. These plaques trigger a cascade of events, ultimately leading to the formation of tau tangles, which disrupt neuronal function and cause cell death. Lecanemab is a humanized IgG1 monoclonal antibody specifically designed to target and bind to these amyloid plaques.
As Dr. Chin Ai-Vyrn of Subang Jaya Medical Centre explained, lecanemab works by stimulating the body’s immune system to clear the amyloid plaques from the brain. This process, known as immunotherapy, aims to reduce the toxic burden of amyloid and slow down the progression of the disease. However, it’s crucial to understand that amyloid is not the sole driver of Alzheimer’s. Tau pathology and other factors also contribute to the disease process, meaning lecanemab addresses a significant, but not complete, aspect of the illness.
Clinical Trial Data and Regulatory Pathways
The efficacy of lecanemab has been demonstrated in several clinical trials, most notably the Phase 3 Clarity AD trial. This double-blind, placebo-controlled trial, involving 1,795 participants with early symptomatic Alzheimer’s disease, showed that lecanemab slowed cognitive decline by 27% compared to placebo over 18 months, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale. Subgroup analysis presented at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting in 2025 suggested a potential delay in disease progression of up to 8.3 years for certain individuals with lower levels of tau protein.
The drug received accelerated approval from the U.S. Food and Drug Administration (FDA) in January 2023, based on the surrogate endpoint of amyloid reduction. Full approval followed in July 2023, contingent upon continued benefit-risk evaluation in post-approval studies. The European Medicines Agency (EMA) is currently reviewing lecanemab, with a decision expected in the coming months. Malaysia’s approval, granted by the NPRA, signifies a commitment to providing access to innovative treatments for Alzheimer’s patients.
Lecanemab: Clarity AD Trial Demographics & Efficacy
| Characteristic | Lecanemab Group (N=898) | Placebo Group (N=897) |
|---|---|---|
| Imply Age (years) | 73.0 | 73.2 |
| Female (%) | 46.8 | 46.2 |
| APOE4 Carrier (%) | 42.1 | 42.3 |
| CDR-SB Change from Baseline (18 months) | +1.21 | +1.66 |
| Percent with ≥1 Amyloid-Related Imaging Abnormality-Edema (ARIA-E) | 12.5% | 1.8% |
Funding and Potential Biases
It’s important to acknowledge the funding sources behind the development of lecanemab. The Clarity AD trial was sponsored by Eisai Co., Ltd., and Biogen Inc., the pharmaceutical companies that jointly developed the drug. While these companies have a vested interest in the success of lecanemab, the trial data has been rigorously reviewed by regulatory agencies and published in peer-reviewed journals. However, potential biases inherent in industry-sponsored research should always be considered.
“The approval of lecanemab represents a significant step forward in our fight against Alzheimer’s disease. While not a cure, it offers a latest avenue for slowing disease progression and improving the lives of patients and their families.” – Dr. Billy Dunn, Director of the Office of Neuroscience at the FDA.
Contraindications & When to Consult a Doctor
Lecanemab is not suitable for all patients with Alzheimer’s disease. It is specifically approved for individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease, confirmed by biomarker evidence of amyloid pathology. Patients with significant cerebrovascular disease, including a history of stroke or brain bleeds, should not receive lecanemab due to the risk of ARIA (Amyloid-Related Imaging Abnormalities), which can include brain swelling and microhemorrhages. Individuals with the APOE4 gene variant may also be at increased risk of ARIA and require closer monitoring.
Any new or worsening neurological symptoms, such as headache, confusion, vision changes, or seizures, should be reported to a physician immediately. Regular MRI scans are necessary to monitor for ARIA during treatment. Consult a neurologist or geriatrician experienced in Alzheimer’s disease diagnosis and management to determine if lecanemab is an appropriate treatment option.
The Future of Alzheimer’s Treatment
The approval of lecanemab marks a turning point in Alzheimer’s research and treatment. While challenges remain, including the high cost of the drug and the demand for specialized diagnostic infrastructure, it offers a glimmer of hope for patients and families affected by this devastating disease. Further research is focused on developing more effective therapies that target multiple aspects of Alzheimer’s pathology, including tau protein and neuroinflammation. Lifestyle interventions, such as regular exercise, a healthy diet, and cognitive stimulation, continue to play a crucial role in reducing the risk of developing Alzheimer’s and slowing its progression.
References
- van Dyck CH, Swanson CJ, Spiegel S, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2215397
- Cummings JL, Zhong X, Merrilees J, et al. Lecanemab demonstrates disease-modifying effects in early Alzheimer’s disease: results from the Clarity AD trial. Alzheimer’s & Dementia. 2023;19(S1):e12818. https://alz-journals.onlinelibrary.wiley.com/doi/abs/10.1002/alz.12818
- FDA Approves First-of-its-Kind Treatment to Slow Alzheimer’s Disease. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-treatment-slow-alzheimers-disease
